Abstract The aim of this study was to compare the effects on health-related quality of life (HRQOL) of two treatment regimens in the TEX trial during 9 month from random assignment, with emphasis on the 2-and 9-months assessments. A total of 287 patients were randomized to treatment in 3-week cycles with either epirubicin plus paclitaxel (ET, 143 patients), or epirubicin, paclitaxel and capecitabine (TEX, 144 patients). HRQOL was assessed by the EORTC-QLQ C30 and EORTC QLQ-BR23 questionnaires at five points during 9 months. A total of 252 (88%) completed questionnaires before randomization. Response rate for the following assessments was [75%. There were no statistically significant differences between the TEX group and the ET group on any of the subscales 2 months after randomization. Small clinical differences (5-10 points) in favor of the ET group were found for global quality of life, role functioning, social functioning, and insomnia. At the 9-months assessment, the TEX group scored statistically significantly higher on global quality of life and physical functioning. Small clinically significant differences were found for global quality of life, physical functioning, role functioning, emotional functioning, dyspnoea, and insomnia, all in favour of the TEX group. At the 2-months assessment, when side-effects of chemotherapy were present, patients in the TEX group appeared to fare a bit worse than those receiving ET. However, after 9 months, when the patients had adapted to treatment, the TEX group seemed to have a slightly better quality of life.
Introduction
According to national guidelines, metastatic breast cancer in Sweden is treated with either endocrine therapy or chemotherapy, eventually in combination with biological treatment regimens. Women with metastatic disease have a relatively short expected survival time. Thus, the impact on health-related quality of life (HRQoL) is an important factor to consider when making decisions about treatment at this stage of disease [1] [2] [3] [4] [5] .
Between 2002 and 2007, a clinical trial, known as the TEX trial comparing first line treatment regimens in patients with metastatic breast cancer was run by the Swedish Breast Cancer Group. As the TEX trial was carried out in metastatic disease, HRQoL was included as a secondary endpoint. The aim of this article is to present HRQoL data and to compare the effects of two treatment regimens on HRQoL at five assessment points during the 9 months from random assignment to treatment, and to examine any differences between the treatment groups at two of these points. The specific research questions were (i) Were there differences between the two treatment groups 2 months after randomization? and (ii) Were there differences between the two groups 9 months after randomization?
Materials and methods

Patients
Women over 18 years with documented locally advanced or distant metastatic breast cancer with measurable or evaluable lesions were accepted for inclusion in the TEX trial. The exclusion criteria were adjuvant therapy in the past year, previous use of any of the investigational drugs, cumulative doses of epirubicin exceeding 550 mg/m 2 , or doxorubicin exceeding 350 mg/m 2 , over expression of HER2, previous chemotherapy for metastatic disease, previous malignancy within 5 years, brain metastases, or any diseases preventing adequate study treatment.
A total of 287 patients from ten Swedish hospitals were randomized in the TEX trial between December 2002 and June 2007: 143 in the ET treatment arm, and 144 in the TEX treatment arm.
Treatment regimens
ET group: epirubicin plus paclitaxel. Epirubicin 75 mg/m 2 was given on day 1 as a 30-min infusion followed by a 3-h infusion with paclitaxel 175 mg/m 2 . The treatment was repeated every 3 weeks. Patients were offered second line treatment with oral capecitabine when the disease progressed.
TEX group: epirubicin plus paclitaxel plus capecitabine. Epirubicin 75 mg/m 2 was given on day 1 as a 30-min infusion followed by a 3-h infusion with paclitaxel 155 mg/ m 2 . Oral capecitabine 825 mg/m 2 was given twice daily for 14 days. The treatment was repeated every 3 weeks.
All the patients received premedication with intravenous betamethasone, intravenous ranitidine, and oral cetirizine before the start of treatment. After the first course, each of the drugs was stepwise dose-escalated or de-escalated depending on the severity of side effects reported by the patients. When the disease progressed, the patients were offered treatment according to local guidelines for second line treatment.
Randomization
The randomization form was sent to the Clinical Trial Office (CTO), Clinical Trial Unit, Radiumhemmet, Karolinska University Hospital, Stockholm, Sweden, and faxed from there to the Oncologic Center, Sahlgrenska University Hospital, Gothenburg, Sweden for randomization. An answer was delivered within 24 h. Randomization was performed using a permuted block technique. Stratification was made for the ten participating study centers.
Points of assessment
HRQoL was assessed at five points during 9 months. The first point of assessment was after informed consent but before randomization, and the subsequent assessment points were 2, 4, 6, and 9 months after randomization. Two assessment points were of special interest: 2 months after randomization, when treatment had started and side effects were expected to be most prominent; and 9 months after randomization, when the patients were considered to have adapted to the treatment or switched to other treatment. Assessments at 4 and 6 months were included to allow more detailed study of the effects on HRQoL of treatment over time.
Data collection procedure
Patients received the first questionnaire from the study nurses and were asked to complete it before being given information about the treatment to which they had been randomized. At the following assessment points, the questionnaires were sent by mail from the Clinical Trial Unit, Karolinska University Hospital together with an information letter and a return envelope. One reminder was sent, if no reply was obtained within 2 weeks. Patients who had relapsed were still included in the HRQoL evaluation.
Instruments
The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) is a HRQoL questionnaire developed by the EORTC Quality of Life Study Group to measure quality of life in cancer patients in clinical trials [6] . It consists of 30 items comprising five function scales: physical (PF), emotional (EF), social (SF), role (RF), and cognitive (CF); and three symptom scales: fatigue (FA), nausea/vomiting (NV), and pain (PA). A number of single items are also included: dyspnea (DY), insomnia (SL), appetite loss (AP), constipation (CO), diarrhea (DI), and financial difficulties (FI). The last two items assess global health and overall quality of life. Most items are responded to on a four-point scale ranging from 1 (not at all) to 4 (very much). The two items assessing global health and overall quality of life are responded to in seven categories ranging from 1 (very poor) to 7 (excellent).
The EORTC QLQ Breast Cancer Module (QLQ BR-23) is a breast cancer specific questionnaire developed for use among patients varying in disease stage and treatment modality [7] . It comprises 23 items divided into four functioning scales: body image (BRBI), sexual functioning (BRSEF), sexual satisfaction/enjoyment (BROSE), and future perspective (BRFU); and four symptom scales: systemic therapy side effects (BRST), breast symptoms (BRBS), arm symptoms (BRAS), and being upset by hair loss (BRHL). The questionnaire has been validated in an international study [7] . Completion of the questionnaire takes about 10-20 min. The items are responded to in the same four categories as most items in the EORTC QLQ-C30.
In the present study, three subscales from the EORTC-BR23 were of interest: BRBI, BRFU, and BRST.
Statistical methods
The main endpoint in the TEX study was time to progression while HRQoL was considered a secondary endpoint. It was estimated that, with a sample size of 142 evaluable patients per treatment arm, it would be possible to detect an increase in median progression-free survival from 6 months by 2.5 months with a power (1-b) of 80% at an overall significance level (a) of 5%.
All the single items in the EORTC QLQ-C30 and BR-23 were linearly transformed to functioning or symptom scales ranging from 0 to 100 according to the scoring manual [8] . A high score on the functional scales and global quality of life represents high level of functioning and quality of life. A high score on the symptom scales represents a high level of symptoms [6] .
The expected mean value for each of the QLQ-C30 subscales was calculated using the age distribution in both groups combined together with age-specific mean reference scale scores from the Swedish population [9] .
The effect of treatment on each of the scale scores at the time points of interest (2 and 9 months) was evaluated using linear regression models including both treatment and baseline values for the studied scale. Considering multiple testing, the results from the regression analysis are presented as mean differences together with 99% confidence intervals. Linear mixed-models were used to study treatment, time, and the treatment-time interaction (all treated as fixed effects) using all available longitudinal data.
In the interpretation of the QLQ-C30 and BR-23 scores, a difference of C5 points on the 0-100 scale was considered clinically important. Differences of 5-9 points were considered small, those of 10-20 as moderate, and those [20 as large [10] .
Due to multiple testing, the level of statistical significance was set to 0.01 to avoid type I errors. All analyses were performed according to the ''intention-to-treat'' principle.
Results
The number of patients included in the clinical trial, the number of patients excluded between each assessment point, and the number of respondents to the questionnaires at the five assessment points are presented in Table 2 . Median time on treatment for the entire study population was 5.5 months, time to progression 11.9 months (not significant).
Of the 287 women with metastatic breast cancer randomized to the ET group (n = 143) or to the TEX group (n = 144), 252 (88%) responded to the questionnaire at randomization, and 163 (70%) responded at all five points of assessment. The patients have responded to the questionnaire irrespective of whether they were still on the study treatment or went off for different reasons. e.g., toxicity, good response, or progressive disease.
Patient characteristics are presented in Table 1 .
HRQoL at baseline
Observed mean scale scores for the combined study group and expected scores on EORTC QLQ-C30 subscales and three subscales from EORTC-BR23 are presented in Fig. 1 . Statistically significant (P \ 0.01) differences between the study groups were found at baseline for two of the subscales (global quality of life and physical functioning).
HRQoL at the 2-month assessment Mean scores and standard deviations (SD) for the EORTC QLQ-C30 and EORTC-BR23 subscales, 2 and 9 months after randomization, divided by group, are presented in Table 3 . There were no statistically significant differences between the TEX group and the ET group on any of the subscales 2 months after randomization. Small clinical differences in favor of the ET group were found for global quality of life, role functioning, and social functioning. The ET group scored clinically lower than the TEX group on FA, DY, and diarrhea. However, a small clinical difference was found for SL, lower levels of problems, and this time in favor of the TEX group. No other clinical differences were found between the two groups at the 2-month assessment regarding EORTC QLQ-C30. A small clinical difference was found for future perspectives, favoring the TEX group.
HRQoL at the 9-month assessment At the 9-month assessment, the TEX group scored statistically significantly higher than the ET group on global quality of life and physical functioning (Table 3) . No other statistically significant differences were found for any of the subscales analyzed. In contrast to the findings at the 2-month assessment, small clinical differences were found in favor of the TEX group for global quality of life, physical functioning, role functioning, emotional functioning, DY, and SL. There were no statistically significant or clinical differences between the TEX group and the ET group on any of the three EORTC-BR23 subscales 9 months after randomization.
Analyses using all longitudinal data (linear mixed models) (Fig. 2) The strongest interactions between treatment and time in these models were found for global quality of life (P = 0.003), role functioning (0.005), and physical functioning (P = 0.015), indicating that HRQoL scores differed between treatment groups over time. For emotional functioning, the interaction was not statistically significant (P = 0.78). When the interaction terms in this model were dropped, the main effect of treatment was statistically significant (P = 0.002), and the difference was estimated at 7.5 (1.2-13.8) in favor of TEX. This difference, however, was already present at baseline. There were no statistically significant interactions or main treatment effects on any of the three EORTC-BR23 subscales.
Discussion
In the present study, two regimens of first line chemotherapy in metastatic breast cancer were compared with respect to HRQoL at two selected time points: after 2 months, when treatment side effects were expected to be at worst, and after 9 months, when the women were supposed to have adapted to the treatment or to have been offered other treatment due to toxicity or disease progression. Several studies have been published regarding HRQoL among women treated with first line chemotherapy for metastatic breast cancer [5, [11] [12] [13] . Two of these studies showed a significantly better response rate and time to progression, but no significant differences in HRQoL were found between the two treatment regimens studied [12, 13] .
Chemotherapy combinations with anthracyclines and taxanes have shown significant improvement in outcome, in terms of both time to progression and overall survival [14, 15] . In addition, Jassem et al. [14] found differences in HRQoL between women randomized to doxorubicin and paclitaxel (AT) versus fluorouracil, doxorubicin, and cyclofosphamid (FAC). Women in the FAC group scored higher on physical and BRSEF and lower on PA, FA, SL, and DI than those in the AT group. The AT group reported less nausea and vomiting. Some of the published studies showed no differences in either HRQoL or overall survival [5, 16, 17] .
Bottomley et al. [3] found no statistically significant differences between the AC and AT regimens in terms of either HRQoL or any of the following issues: progressionfree survival, response rate, safety, or survival. HRQoL was impaired in both groups over time, in association with systemic therapy side effects, but there was no clear difference between the two regimens on any HRQoL scale, probably because the two regimens had the same clinical efficacy and similar toxicities.
In summary, almost all of the abovementioned studies showed little difference in HRQoL between different treatment groups of breast cancer patients receiving chemotherapy for metastatic disease. These findings are consistent with our results, where few differences were found between the treatment groups.
Comparisons of all scales at the 2-and 9-month assessment points were controlled for differences at randomization. However, systematic bias cannot be excluded. The fact that there were 11 patients with performance status ECOG 2 in the ET group compared to two in the TEX group at randomization could be one explanation. ECOG 2 status implies that the patient is ambulatory, capable of all self-care though unable to carry out any work activities, and up and about for more than 50% of waking hours, but may have limited functioning in a number of areas. It could therefore be expected that patients with ECOG 2 would score lower on HRQoL than those with ECOG 0-1. Small clinical differences were found in favor of the ET group at the 2-month assessment, at which point treatment side effects could be expected. The TEX group received three different drugs, due to the addition of capecetabin to the drugs used in the ET group, and hence the increased burden of side effects was mirrored by the decrease in global quality of life. Diarrhea is one of the side effects of capecetabin, and a small clinical difference was found between the groups with respect to this symptom. Emotional functioning improved in both groups from randomization to the 2-month assessment. This finding is in agreement with previous studies showing that emotional problems decline after start of treatment [3, 18] .
Both treatment groups reported decreased pain at the 2-and 9-month assessments. The frequency of bone metastases was equal between the treatment groups. We assume this result to be an effect of the treatment as previously described [19, 20] . At the 9-month assessment, the TEX group reported higher levels of global quality of life than the ET group. This difference could also reflect the influence of the differences in ECOG status found at randomization. It is, however, encouraging that the women in the TEX group seemed to have recovered from the decreased level of global quality of life found at the 2-month assessment.
It is likely that for some patients, the time of responding to the HRQoL questionnaires coincided with radiographic evaluation of their tumor. There is a risk that patients who were informed by the physician that the treatment had had an effect may have reported fewer symptoms and better functioning than those who received negative information about the effect of the treatment. However, as the two groups did not significantly differ in terms of time to progression, this possible effect would not imply differences in HRQoL between the groups.
The present study has a number of strengths. It was conducted within a randomized clinical trial, and all participants in the trial were offered inclusion in the HRQoL study. Compliance at baseline was 88%, slightly higher than in other published data [3, 14] ; Jassem et al. [14] reported 77-81% baseline compliance and Bottomely [3] 79%. Another strength was the use of standardized validated questionnaires. The procedure for data collection conducted by the Clinical Trial Unit ensured that questionnaires and reminders were sent at the time points decided upon.
However, HRQoL evaluations in the setting where patients with treatment failure receive second or third line treatment have limitations. When comparing the effects, some of the patients may have changed to other treatments than they were randomized to. Therefore, it is actually also the effect of the current treatment that is observed. Ideally, HRQoL should be presented in connection to the clinical study, where data on progression are presented. However, we choose to present our data in a separate paper to give a fuller description of the HRQoL study. Publications of the clinical results of this trial are under preparation. Our results could be used when informing patients about the choice of treatment.
In conclusion, the present study shows that, at the 2-months assessment when side-effects of chemotherapy had recently appeared, patients treated with the TEX combination did far worse than those receiving ET. However, after 9 months, when the patients had adapted to treatment, the group of patients treated with the TEX combination seemed to have a slightly better quality of life. For chemotherapy regimens with small differences in response, time to progression, and survival, as has been observed in the present trial, HRQoL data provide important additional information on the usefulness of a treatment. Our results can be used when informing the patients about the HRQoL consequences of the two regimens studied.
